Predicine was founded in 2015 to address unmet clinical challenges in precision oncology. For patients with metastatic castration-resistant prostate cancer, these challenges include the difficulties of obtaining bone tumor tissue from metastatic sites and the technical challenges in liquid biopsy assays to detect gene deletions.
These challenges create barriers to patients potentially receiving targeted therapies. Over the past several months, Predicine and collaborators have published several manuscripts highlighting the impact of the company’s innovative liquid biopsy solutions to improve care for patients with prostate cancer.
In this webinar, Predicine’s Founder & CEO, Dr. Shidong Jia, will review data from the recent studies demonstrating the power of Predicine’s innovative liquid biopsy assays to advance the treatment of prostate cancer.
Date: Tuesday, September 28th
Time: 1:00 PM EDT / 10 AM PDT
Topics to be covered:
Title: Addressing Unmet Clinical Challenges for Patients with Prostate Cancer
Date: Tuesday, September 28th, 2021
Time: 1:00pm Eastern Standard Time
Duration: 45 minutes
Speaker: Dr. Shidong Jia, Founder and CEO of Predicine, Inc.
